BRPI0413709A - compostos para o tratamento de distúrbios neurodegenerativos - Google Patents

compostos para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0413709A
BRPI0413709A BRPI0413709-4A BRPI0413709A BRPI0413709A BR PI0413709 A BRPI0413709 A BR PI0413709A BR PI0413709 A BRPI0413709 A BR PI0413709A BR PI0413709 A BRPI0413709 A BR PI0413709A
Authority
BR
Brazil
Prior art keywords
compounds
treatment
neurodegenerative disorders
formula
relates
Prior art date
Application number
BRPI0413709-4A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413709A publication Critical patent/BRPI0413709A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS". A presente invenção refere-se a compostos da fórmula em que R¬ 3¬, R¬ 5¬, R¬ 7¬, U, X, Y e Z são como definidos. Os compostos da fórmula I têm atividade de inibição da produção do peptídeo A<225>. Esta invenção refere-se também a ccomposições farmacêuticas e métodos de tratamento de doenças, por exemplo, doenças neurodegenerativas, por exemplo, doença de Alzheimer, em um mamífero compreendendo compostos da fórmula I.
BRPI0413709-4A 2003-08-21 2004-08-18 compostos para o tratamento de distúrbios neurodegenerativos BRPI0413709A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49673503P 2003-08-21 2003-08-21
PCT/US2004/026854 WO2005020991A1 (en) 2003-08-21 2004-08-18 Compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0413709A true BRPI0413709A (pt) 2006-10-17

Family

ID=34272502

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413709-4A BRPI0413709A (pt) 2003-08-21 2004-08-18 compostos para o tratamento de distúrbios neurodegenerativos

Country Status (11)

Country Link
US (3) US7253195B2 (pt)
EP (1) EP1658072A4 (pt)
JP (1) JP2007502828A (pt)
AR (1) AR045474A1 (pt)
BR (1) BRPI0413709A (pt)
CA (1) CA2534532A1 (pt)
MX (1) MXPA06001845A (pt)
PA (1) PA8609801A1 (pt)
TW (1) TW200526610A (pt)
UY (1) UY28484A1 (pt)
WO (1) WO2005020991A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658072A4 (en) * 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
DK1730119T3 (da) * 2004-03-23 2008-08-11 Pfizer Prod Inc Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
EP1809282B1 (en) * 2004-10-18 2013-01-09 Amgen, Inc Thiadiazole compounds and methods of use
AU2006293619A1 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
US8541406B2 (en) 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
GB0623258D0 (en) 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
GB0704394D0 (en) * 2007-03-07 2007-04-11 Senexis Ltd Compounds
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
JP5705748B2 (ja) 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10029244B2 (en) 2013-02-05 2018-07-24 Basf Se Process for preparing a titanium-containing zeolitic material having an MWW framework structure
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
DK3634394T3 (da) * 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
EP4055011A1 (en) * 2019-11-05 2022-09-14 Dermira, Inc Mrgprx2 antagonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1021424E (pt) * 1996-06-21 2003-06-30 Upjohn Co Amidas de tiadiazolo como inibidores da metaloproteinase de matriz
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1658072A4 (en) 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases

Also Published As

Publication number Publication date
UY28484A1 (es) 2005-03-31
US20080249094A1 (en) 2008-10-09
WO2005020991A1 (en) 2005-03-10
EP1658072A4 (en) 2009-03-25
US7408068B2 (en) 2008-08-05
JP2007502828A (ja) 2007-02-15
EP1658072A1 (en) 2006-05-24
CA2534532A1 (en) 2005-03-10
US20050043372A1 (en) 2005-02-24
TW200526610A (en) 2005-08-16
AR045474A1 (es) 2005-10-26
US7253195B2 (en) 2007-08-07
MXPA06001845A (es) 2006-05-04
PA8609801A1 (es) 2005-05-24
US20070270426A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BRPI0409721A (pt) compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
BRPI0413349A (pt) compostos de oxazol para o tratamento de doenças neurodegenerativas
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
BRPI0509386A (pt) compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
DOP2004000966A (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.